Horizon Investments LLC Buys 42 Shares of Insulet Co. (NASDAQ:PODD)

Horizon Investments LLC grew its stake in shares of Insulet Co. (NASDAQ:PODD) by 3.1% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,387 shares of the medical instruments supplier’s stock after acquiring an additional 42 shares during the period. Horizon Investments LLC’s holdings in Insulet were worth $362,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. SBI Securities Co. Ltd. purchased a new position in Insulet during the fourth quarter valued at approximately $36,000. SRS Capital Advisors Inc. increased its holdings in Insulet by 43.1% during the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after buying an additional 56 shares during the period. Friedenthal Financial purchased a new position in Insulet during the fourth quarter valued at approximately $57,000. TD Private Client Wealth LLC increased its holdings in Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after buying an additional 56 shares during the period. Finally, Assetmark Inc. increased its holdings in Insulet by 1,447.1% during the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock valued at $69,000 after buying an additional 246 shares during the period.

Analyst Ratings Changes

Several brokerages recently issued reports on PODD. Wells Fargo & Company lifted their price objective on shares of Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a report on Friday, February 21st. StockNews.com lowered shares of Insulet from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Piper Sandler lifted their price target on shares of Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Stifel Nicolaus lifted their price target on shares of Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a report on Friday, February 21st. Finally, Canaccord Genuity Group lifted their price target on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $292.06.

Insider Activity at Insulet

In related news, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.47% of the stock is currently owned by insiders.

Insulet Trading Down 0.2 %

NASDAQ:PODD opened at $265.39 on Friday. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $289.46. The firm has a fifty day simple moving average of $272.11 and a 200-day simple moving average of $256.26. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The company has a market capitalization of $18.64 billion, a P/E ratio of 45.84, a PEG ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. The company had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. On average, equities research analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.